Abstract
The combination of irinotecan and fluorouracil (5-FU) is synergistic when applied to human colon cancer cell lines in vitro and appears to be schedule-dependent: maximal activity occurs when irinotecan is administered prior to 5-FU. In this phase I study, irinotecan is administered in combination with UFT and leucovorin in patients with advanced solid tumors. Irinotecan is given as a 90-minute intravenous infusion on day 1 followed by twice-daily UFT plus oral leucovorin on days 2 through 15. Cycles are repeated every 21 days. Five patients have been treated to date; four are evaluable for toxicity. Starting doses were irinotecan 200 mg/m2/day, UFT 200 mg/m2/day, and leucovorin 60 mg/day. Preliminary results indicate that irinotecan in combination with UFT plus leucovorin is well tolerated at the initial doses (described in this article).
Publication types
-
Clinical Trial
-
Clinical Trial, Phase I
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Administration, Oral
-
Aged
-
Antineoplastic Agents, Phytogenic / administration & dosage
-
Antineoplastic Agents, Phytogenic / adverse effects
-
Antineoplastic Agents, Phytogenic / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Camptothecin / administration & dosage
-
Camptothecin / adverse effects
-
Camptothecin / analogs & derivatives*
-
Camptothecin / therapeutic use*
-
Dose-Response Relationship, Drug
-
Drug Therapy, Combination
-
Female
-
Humans
-
Infusions, Intravenous
-
Irinotecan
-
Leucovorin / administration & dosage
-
Male
-
Middle Aged
-
Neoplasms / drug therapy*
-
Tegafur / administration & dosage
-
Uracil / administration & dosage
Substances
-
Antineoplastic Agents, Phytogenic
-
Tegafur
-
Uracil
-
Irinotecan
-
Leucovorin
-
Camptothecin